HIND Key Statistics, Chart & Performance
The current stock price of HIND is 2.67 USD. In the past month the price decreased by -28.81%.
HIND Technical Analysis
HIND Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HIND. The financial health of HIND is average, but there are quite some concerns on its profitability.
HIND Financial Highlights
Over the last trailing twelve months HIND reported a non-GAAP Earnings per Share(EPS) of -183.13. The EPS increased by 90.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -161.11% | ||
| ROE | -448.7% | ||
| Debt/Equity | 0 |
HIND Forecast & Estimates
7 analysts have analysed HIND and the average price target is 15.3 USD. This implies a price increase of 473.03% is expected in the next year compared to the current price of 2.67.
For the next year, analysts expect an EPS growth of -604.44% and a revenue growth -97.51% for HIND
HIND Ownership
HIND Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.9 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20.81 | 520.41B | ||
| MRK | MERCK & CO. INC. | 12.61 | 275.70B | ||
| PFE | PFIZER INC | 8.03 | 146.04B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.2 | 109.50B | ||
| ZTS | ZOETIS INC | 19.78 | 55.25B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.83B | ||
| VTRS | VIATRIS INC | 5.6 | 15.04B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.36 | 12.10B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.27B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.43B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 5.57B |
Related stock screener links
About HIND
Company Profile
Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. The company is headquartered in San Clemente, California and currently employs 17 full-time employees. The company went IPO on 2016-10-06. The firm is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.
Company Info
VYOME HOLDINGS INC
1001 Calle Amanecer
San Clemente CALIFORNIA US
Employees: 17
Phone: 19494296680
VYOME HOLDINGS INC / HIND FAQ
Can you describe the business of VYOME HOLDINGS INC?
Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. The company is headquartered in San Clemente, California and currently employs 17 full-time employees. The company went IPO on 2016-10-06. The firm is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.
Can you provide the latest stock price for VYOME HOLDINGS INC?
The current stock price of HIND is 2.67 USD. The price decreased by -3.26% in the last trading session.
Does HIND stock pay dividends?
HIND does not pay a dividend.
What is the ChartMill technical and fundamental rating of HIND stock?
HIND has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for VYOME HOLDINGS INC?
VYOME HOLDINGS INC (HIND) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the market cap for VYOME HOLDINGS INC?
VYOME HOLDINGS INC (HIND) has a market capitalization of 15.06M USD. This makes HIND a Nano Cap stock.